Newly public Amicus Therapeutics is attracting some positive attention from the analysts, who have been impressed by the company's swift advances on the clinical development front. JP Morgan analyst Geoffrey Meacham notes Amicus' looming Phase III trial for Fabry disease and a scheduled release of mid-stage data on a Gaucher disease candidate in the second half of next year. A third candidate is in Phase I for Pompe disease. Amicus specializes in lysosomal storage diseases, or LSD's. Investors haven't been particularly enthusiastic about the company, though. Amicus went public May 31 at $16 a share and has since seen its stock price slide 20 percent.
- read the report from The Boston Globe
ALSO: A closer look at the IPOs of Amicus Therapeutics, Jazz Pharmaceuticals and Sirtris Pharmaceuticals. Report
Related Articles:
Amicus Therapeutics outlines $86M IPO. Report
Amicus gins $55M in third round, outlines Phase II. Report
Genzyme sees big returns from small drug market. Report